FDA decision on the sBLA for 2seventy bio’s (TSVT) Abecma in 3L multiple myeloma is anticipated following the ODAC meeting on March 15…Close of the asset sale to Regeneron (REGN) is expected in the first half of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TSVT:
- 2Seventy Bio, Inc. (TSVT) Q4 Earnings Cheat Sheet
- 2seventy bio and BMS Schedule FDA Panel for Abecma
- Bristol Myers and 2seventy Bio’s application for Abecma to be reviewed by FDA
- 2seventy Bio upgraded to Outperform at Leerink on acquisition potential
- 2seventy Bio upgraded to Outperform from Market Perform at Leerink
